{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:06:55Z","timestamp":1765487215337,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Regional Health Management of Castilla y Le\u00f3n","award":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"],"award-info":[{"award-number":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"]}]},{"name":"Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation","award":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"],"award-info":[{"award-number":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"]}]},{"name":"Fundaci\u00f3n hna, 2nd edition of the Scientific Health Research Award","award":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"],"award-info":[{"award-number":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"]}]},{"name":"ISCIII and the European Social Fund","award":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"],"award-info":[{"award-number":["GRS 2202\/A\/2020","CD21\/00022","FI20\/00090"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Ibrutinib is a selective Bruton\u2019s tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL). This drug exhibits significant variability in response and toxicity profile, possibly due to genetic polymorphisms in drug-metabolizing enzymes and transporters. The aim of this observational study is to address interindividual variability in the efficacy and safety of ibrutinib treatment in 49 CLL patients. Methods: Genotyping of nine polymorphisms was performed by quantitative polymerase chain reaction (qPCR) using a ViiA7\u00ae PCR Instrument and TaqMan assays, and ibrutinib plasma concentrations were determined using high-performance liquid chromatography coupled to a tandem mass spectrometry detector (HPLC-MS\/MS). Results: Our study confirmed a high response rate, with 62% of patients achieving complete remission (CR), 9% CR with incomplete hematologic recovery (CRi), and 24% partial remission (PR). The impact of genetic polymorphisms on the CR rate was evaluated, revealing no statistically significant associations for CYP3A4, CYP3A5, ABCB1, ABCG2, and SLCO1B1 variants. However, a tendency was observed for patients carrying ABCB1 rs1128503, rs1045642 T\/T, or rs2032582 A\/A genotypes to achieve a higher CR rate. Adverse drug reactions (ADRs) were frequent, with vascular disorders (39%) and infections (27%) being the most common. Genetic polymorphisms influenced ibrutinib toxicity, with CYP3A4 *1\/*22 appearing to be protective against overall ADRs. Conclusions: The unexpected association between CYP3A4 *1\/*22 genotype and lower ADR incidence, as well as the trend toward improved treatment response in patients carrying ABCB1 genotypes, suggests compensatory metabolic mechanisms. However, given the small sample size, larger studies are needed to confirm these findings and their clinical implications, while also aiming to uncover other non-genetic factors that may contribute to a better understanding of the variability in treatment response and toxicity.<\/jats:p>","DOI":"10.3390\/ph18070996","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:08:44Z","timestamp":1751447324000},"page":"996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4694-7469","authenticated-orcid":false,"given":"Noelia","family":"P\u00e9rez-G\u00f3mez","sequence":"first","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Facultad de Ciencias de la Salud, Universidad de Burgos, 09001 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Sanz-Solas","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Pharmacology Department, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alonso-Madrigal","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Santiago Ap\u00f3stol, Miranda de Ebro, 09200 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-3758","authenticated-orcid":false,"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de La Princesa, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"\u00c1lvarez-Nu\u00f1o","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Covadonga","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[{"name":"Grupo 32, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP), Hospital Universitario de La Princesa, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-3268","authenticated-orcid":false,"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal Miguel","family":"Parra-Garc\u00e9s","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-7941","authenticated-orcid":false,"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Vinuesa","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"D\u00edaz-G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1887-4644","authenticated-orcid":false,"given":"Mar\u00eda","family":"Gonz\u00e1lez-Oter","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Cancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid Spanish National Research Council (IBGM; UVa-CSIC), 47003 Valladolid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-7020","authenticated-orcid":false,"given":"Natalia","family":"Garc\u00eda-Sancha","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-3674","authenticated-orcid":false,"given":"Ra\u00fal","family":"Azibeiro-Melchor","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2554","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"},{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-0287","authenticated-orcid":false,"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Facultad de Ciencias de la Salud, Universidad de Burgos, 09001 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.0105-2896.2004.0105.x","article-title":"Basal B-cell receptor signaling in B lymphocytes: Mechanisms of regulation and role in positive selection, differentiation, and peripheral survival","volume":"197","author":"Bannish","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) (2025, February 28). Ficha T\u00e9cnica del Ibrutinib. Ministerio de Sanidad. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/114945002\/FT_114945002.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bcp.12787","article-title":"Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults","volume":"81","author":"Smit","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/clpt.2013.220","article-title":"Genetics, Epigenetics, and Regulation of Drug-Metabolizing Cytochrome P450 Enzymes","volume":"95","author":"Zanger","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_7","first-page":"288","article-title":"High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme","volume":"15","author":"Inglada","year":"2015","journal-title":"Pharm. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"Skee","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-020-00970-x","article-title":"Extrahepatic metabolism of ibrutinib","volume":"39","author":"Rood","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.amjsurg.2016.11.008","article-title":"Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol","volume":"213","author":"Senagore","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dessilly, G., Panin, N., Elens, L., Haufroid, V., and Demoulin, J.B. (2016). Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Sci. Rep., 6.","DOI":"10.1038\/srep29559"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","article-title":"Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins","volume":"94","author":"Schinkel","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","first-page":"93","article-title":"MDR1 gene polymorphisms and clinical relevance","volume":"33","author":"Li","year":"2006","journal-title":"Yi Chuan Xue Bao"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1021\/acs.molpharmaceut.8b00702","article-title":"P-Glycoprotein (MDR1\/ABCB1) Restricts Brain Penetration of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability","volume":"15","author":"Rood","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CAD.0000000000001125","article-title":"Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: A systematic review and meta-analysis","volume":"33","author":"Han","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S202286","article-title":"Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: Results of a single-center retrospective analysis","volume":"10","author":"Nuttall","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated With Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., and McVean, G.A. (2015). A global reference for human genetic variation. Nature, 526, 68\u201374.","DOI":"10.1038\/nature15393"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Prajapati, P., Patel, A., Desai, A., Shah, P., Pulusu, V.S., Haque, A., Kalam, M.A., and Shah, S. (2024). In-vivo pharmacokinetic study of ibrutinib-loaded nanostructured lipid carriers in rat plasma by sensitive spectrofluorimetric method using harmonized approach of quality by design and white analytical chemistry. Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 321.","DOI":"10.1016\/j.saa.2024.124731"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1078155216656929","article-title":"Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia","volume":"23","author":"Marini","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Pinotti","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Evaluaci\u00f3n de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Espa\u00f1ol de Farmacovigilancia","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Cl\u00ednica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Saiz-Rodr\u00edguez, M., Almenara, S., Navares-G\u00f3mez, M., Ochoa, D., Rom\u00e1n, M., Zubiaur, P., Koller, D., Santos, M., Mej\u00eda, G., and Borobia, A.M. (2020). Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines, 8.","DOI":"10.3390\/biomedicines8040094"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00003088-199121030-00004","article-title":"Omeprazole Drug Interaction Studies","volume":"21","author":"Andersson","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"ref_31","unstructured":"Grupo Espa\u00f1ol de Leucemia Linfoc\u00edtica Cronica (2025, June 18). Clinical Practice Guide for the Diagnosis and Treatment of Chronic Lympocytic Leukemia and Small Cell Lympocytic Lymphoma. Available online: https:\/\/www.gellc.es\/guias-clinicas\/24-guia-gellc-2024-pdf\/file."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","article-title":"Therapeutic Drug Monitoring of Imatinib: Bayesian and Alternative Methods to Predict Trough Levels","volume":"51","author":"Gotta","year":"2012","journal-title":"Clin. Pharmacokinet."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:06Z","timestamp":1760032986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18070996"],"URL":"https:\/\/doi.org\/10.3390\/ph18070996","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}